Protective effect of ginsenoside Rg1 on lidocaine-induced apoptosis

Li,Hui; Xu,Junmei; Wang,Xin; Yuan,Guixiu

doi:10.3892/mmr.2013.1822

Protective effect of ginsenoside Rg1 on lidocaine-induced apoptosis

Authors:
- Hui Li
- Junmei Xu
- Xin Wang
- Guixiu Yuan
View Affiliations

Affiliations: Department of Anesthesiology, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, P.R. China
Published online on: November 21, 2013 https://doi.org/10.3892/mmr.2013.1822
Pages: 395-400
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lidocaine, as an anesthetic substance, is often used for surface and spinal anesthesia. However, studies have shown that lidocaine may induce transient neurological symptoms and cauda equina syndrome. In the present study the effects of the ginsenoside Rg1 (Rg1) on lidocaine‑induced apoptosis were assessed in Jurkat cells using flow cytometry and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL). The data showed that incubation with Rg1 provides protection against lidocaine‑induced apoptosis in cultured Jurkat cells. In order to investigate the effect of Rg1 on the apoptosis pathway, caspase 3 gene expression was determined. The results suggested that the protective effect of Rg1 on lidocaine‑induced apoptosis is mediated by altering the level of B‑cell lymphoma‑2 (BCL‑2) family proteins and downregulating caspase‑3 expression. In conclusion, the present study demonstrated that incubation with Rg1 provides protection against lidocaine‑induced apoptosis in cultured Jurkat cells. In addition, the study demonstrated that Rg1 is a notable antiapoptotic molecule that is capable of blocking the caspase‑dependent signaling cascade in Jurkat cells, and that the protective effect of Rg1 on lidocaine‑induced apoptosis is mediated by altering levels of BCL‑2 family proteins and downregulating caspase‑3 expression. The present study provides the basis for understanding and evaluating the effect of Rg1 in the in vivo treatment of lidocaine-induced transient neurological symptoms and cauda equina syndrome by lidocaine.

View Figures

View References

1	Mazoit JX and Cao LS: Local anaesthetic toxicity. Curr Opin Anaesthesiol. 8:409–413. 1995. View Article : Google Scholar
2	Del Valle LJ and Orihuela PA: Cleavage and development in cultured preimplantation mouse embryos exposed to lidocaine. Reprod Toxicol. 10:491–496. 1996.PubMed/NCBI
3	Saadé NE, Al Amin HA, Barchini J, Tchachaghian S, et al: Brainstem injection of lidocaine releases the descending pain-inhibitory mechanisms in a rat model of mononeuropathy. Exp Neurol. 237:180–190. 2012.PubMed/NCBI
4	Friederich P and Schmitz T: Lidocaine-induced cell death in a human model of neuronal apoptosis. Eur J Anaesthesiol. 19:564–570. 2002. View Article : Google Scholar : PubMed/NCBI
5	Johnson ME, Uhl CB, Spittler KH, Wang H and Gores GJ: Mitochondrial injury and caspase activation by the local anesthetic lidocaine. Anesthesiology. 101:1184–1194. 2004. View Article : Google Scholar : PubMed/NCBI
6	Werdehausen R, Braun S, Essmann F, Schulze-Osthoff K, et al: Lidocaine induces apoptosis via the mitochondrial pathway independently of death receptor signaling. Anesthesiology. 107:136–143. 2007. View Article : Google Scholar : PubMed/NCBI
7	Hon CC, Chow YC, Zeng FY and Leung FC: Genetic authentication of ginseng and other traditional Chinese medicine. Acta Pharmacol Sin. 24:841–846. 2003.PubMed/NCBI
8	Qi LW, Wang CZ and Yuan CS: Ginsenosides from American ginseng: chemical and pharmacological diversity. Phytochemistry. 72:689–699. 2011. View Article : Google Scholar : PubMed/NCBI
9	Attele AS, Wu JA and Yuan CS: Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol. 58:1685–1693. 1999. View Article : Google Scholar : PubMed/NCBI
10	Tawab MA, Bahr U, Karas M, Wurglics M and Schubert-Zsilavecz M: Degradation of ginsenosides in humans after oral administration. Drug Metab Dispos. 31:1065–1071. 2003. View Article : Google Scholar : PubMed/NCBI
11	Yi LN, Yin XY, Jiang YF and Liu QS: Preparation and properties of ginsenoside Rg1 molecularly imprinted polymers. Adv Mat Res. 550–553:1715–1718. 2012.PubMed/NCBI
12	Wu J, Pan Z, Wang Z, Zhu W, et al: Ginsenoside Rg1 protection against β-amyloid peptide-induced neuronal apoptosis via estrogen receptor α and glucocorticoid receptor-dependent anti-protein nitration pathway. Neuropharmacology. 63:349–361. 2012.
13	Zhang DF, Xu H, Sun BB, Li JQ, et al: Adjuvant effect of ginsenoside-based nanoparticles (ginsomes) on the recombinant vaccine against Eimeria tenella in chickens. Parasitol Res. 110:2445–2453. 2012. View Article : Google Scholar : PubMed/NCBI
14	Drasner K: Local Anesthetic neurotoxicity and cauda equina syndrome. Complications in regional anesthesia and pain medicine. Neal and Rathmell JP: Lippincott, Williams and Wilkins; Philadelphia, PA, USA: pp. 1252012
15	Vaghadia H, Neilson G and Lennox PH: Selective spinal anesthesia for outpatient transurethral prostatectomy (TURP): randomized controlled comparison of chloroprocaine with lidocaine. Acta Anaesthesiol Scand. 56:217–223. 2012. View Article : Google Scholar
16	Hahnenkamp K, Herroeder S and Hollmann MW: Regional anaesthesia, local anaesthetics and the surgical stress response. Best Pract Res Clin Anaesthesiol. 18:509–527. 2004. View Article : Google Scholar : PubMed/NCBI
17	Hampl KF, Schneider MC, Pargger H, Gut J, et al: A similar incidence of transient neurologic symptoms after spinal anesthesia with 2% and 5% lidocaine. Anesth Analg. 83:1051–1054. 1996.
18	Gerancher JC: Cauda equina syndrome following a single spinal administration of 5% hyperbaric lidocaine through a 25-gauge Whitacre needle. Anesthesiology. 87:687–689. 1997.
19	Zaric D, Christiansen C, Pace NL and Punjasawadwong Y: Transient neurologic symptoms after spinal anesthesia with lidocaine versus other local anesthetics: a systematic review of randomized, controlled trials. Anesth Analg. 100:1811–1816. 2005. View Article : Google Scholar
20	Chan RY, Chen WF, Dong A, Guo D and Wong MS: Estrogen-like activity of ginsenoside Rg1 derived from Panax notoginseng. J Clin Endocrinol Metab. 87:3691–3695. 2002. View Article : Google Scholar : PubMed/NCBI
21	Leung KW, Yung KK, Mak NK, Yue PY, et al: Angiomodulatory and neurological effects of ginsenosides. Curr Med Chem. 14:1371–1380. 2007. View Article : Google Scholar : PubMed/NCBI
22	Saraste A and Pulkki K: Morphologic and biochemical hallmarks of apoptosis. Cardiovasc Res. 45:528–537. 2000. View Article : Google Scholar
23	Slee EA, Adrain C and Martin SJ: Executioner caspase-3, -6 and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J Biol Chem. 276:7320–7326. 2001. View Article : Google Scholar : PubMed/NCBI
24	Fan TJ, Han LH, Cong RS and Liang J: Caspase family proteases and apoptosis. Acta Biochim Biophys Sin (Shanghai). 37:719–727. 2005. View Article : Google Scholar : PubMed/NCBI
25	Jänicke RU, Sprengart ML, Wati MR and Porter AG: Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem. 273:9357–9360. 1998.
26	Porter AG and Jänicke RU: Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 6:99–104. 1999. View Article : Google Scholar : PubMed/NCBI
27	Dai ZJ, Gao J, Ji ZZ, Wang XJ, et al: Matrine induces apoptosis in gastric carcinoma cells via alteration of Fas/FasL and activation of caspase-3. J Ethnopharmacol. 123:91–96. 2009. View Article : Google Scholar : PubMed/NCBI
28	Chipuk JE and Green DR: How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol. 18:157–164. 2008. View Article : Google Scholar : PubMed/NCBI
29	Hengartner MO: The biochemistry of apoptosis. Nature. 407:770–776. 2000. View Article : Google Scholar : PubMed/NCBI
30	Danial NN and Korsmeyer SJ: Cell death: critical control points. Cell. 116:205–219. 2004. View Article : Google Scholar : PubMed/NCBI
31	Cheng EH, Wei MC, Weiler S, Flavell RA, et al: BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell. 8:705–711. 2001. View Article : Google Scholar : PubMed/NCBI
32	Reed JC: Bcl-2 family proteins. Oncogene. 17:3225–3236. 1998. View Article : Google Scholar
33	Li W, Ma N, Ong LL, Nesselmann C, et al: Bcl-2 engineered MSCs inhibited apoptosis and improved heart function. Stem Cells. 25:2118–2127. 2007. View Article : Google Scholar : PubMed/NCBI
34	MacLellan WR and Schneider MD: Death by design. Programmed cell death in cardiovascular biology and disease. Circ Res. 81:137–144. 1997. View Article : Google Scholar : PubMed/NCBI
35	Kim EC, Yun BS, Ryoo IJ, Min JK, et al: Complestatin prevents apoptotic cell death: inhibition of a mitochondrial caspase pathway through AKT/PKB activation. Biochem Biophys Res Commun. 313:193–204. 2004. View Article : Google Scholar : PubMed/NCBI
36	Min JK, Kim JH, Cho YL, Maeng YS, et al: 20(S)-Ginsenoside Rg3 prevents endothelial cell apoptosis via inhibition of a mitochondrial caspase pathway. Biochem Biophys Res Commun. 349:987–994. 2006. View Article : Google Scholar : PubMed/NCBI